Uveal Melanoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Uveal Melanoma – Pipeline Review, H2 2016’, provides an overview of the Uveal Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma

The report reviews pipeline therapeutics for Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Uveal Melanoma therapeutics and enlists all their major and minor projects

The report assesses Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Uveal Melanoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aura Biosciences, Inc.

Bellicum Pharmaceuticals, Inc.

Celldex Therapeutics, Inc.

Cleveland BioLabs, Inc.

Eli Lilly and Company

Iconic Therapeutics, Inc.

Immunocore Limited

Navigen Pharmaceuticals, Inc.

Novartis AG

PEP-Therapy SAS

Pfizer Inc.

Spectrum Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Uveal Melanoma Overview 9

Therapeutics Development 10

Pipeline Products for Uveal Melanoma - Overview 10

Pipeline Products for Uveal Melanoma - Comparative Analysis 11

Uveal Melanoma - Therapeutics under Development by Companies 12

Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 13

Uveal Melanoma - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Uveal Melanoma - Products under Development by Companies 17

Uveal Melanoma - Products under Investigation by Universities/Institutes 18

Uveal Melanoma - Companies Involved in Therapeutics Development 19

Aura Biosciences, Inc. 19

Bellicum Pharmaceuticals, Inc. 20

Celldex Therapeutics, Inc. 21

Cleveland BioLabs, Inc. 22

Eli Lilly and Company 23

Iconic Therapeutics, Inc. 24

Immunocore Limited 25

Navigen Pharmaceuticals, Inc. 26

Novartis AG 27

PEP-Therapy SAS 28

Pfizer Inc. 29

Spectrum Pharmaceuticals, Inc. 30

Uveal Melanoma - Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 35

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

alpelisib - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

AU-011 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

BPX-701 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

crizotinib - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

DPTC-9h - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

emibetuzumab - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

entolimod - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

glembatumumab vedotin - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

hI-con1 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

HPH-196 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

HPH-211 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

IMCgp-100 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

KCN-1 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

LXS-196 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

merestinib - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

NAV-2729 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

nutlin-3 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

pasireotide ER - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

sotrastaurin acetate - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

sunitinib malate - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Vaccine 2 for Melanoma - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

Vaccine for Oncology - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

vincristine sulfate - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

Uveal Melanoma - Dormant Projects 100

Uveal Melanoma - Discontinued Products 101

Uveal Melanoma - Product Development Milestones 102

Featured News & Press Releases 102

Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 102

Mar 30, 2016: Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma 102

Jan 25, 2016: Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma 103

Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 103

Sep 09, 2015: Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme 104

Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma 104

May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma 105

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Tables

List of Tables

Number of Products under Development for Uveal Melanoma, H2 2016 10

Number of Products under Development for Uveal Melanoma – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Uveal Melanoma – Pipeline by Aura Biosciences, Inc., H2 2016 19

Uveal Melanoma – Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 20

Uveal Melanoma – Pipeline by Celldex Therapeutics, Inc., H2 2016 21

Uveal Melanoma – Pipeline by Cleveland BioLabs, Inc., H2 2016 22

Uveal Melanoma – Pipeline by Eli Lilly and Company, H2 2016 23

Uveal Melanoma – Pipeline by Iconic Therapeutics, Inc., H2 2016 24

Uveal Melanoma – Pipeline by Immunocore Limited, H2 2016 25

Uveal Melanoma – Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 26

Uveal Melanoma – Pipeline by Novartis AG, H2 2016 27

Uveal Melanoma – Pipeline by PEP-Therapy SAS, H2 2016 28

Uveal Melanoma – Pipeline by Pfizer Inc., H2 2016 29

Uveal Melanoma – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 30

Assessment by Monotherapy Products, H2 2016 31

Number of Products by Stage and Target, H2 2016 33

Number of Products by Stage and Mechanism of Action, H2 2016 36

Number of Products by Stage and Route of Administration, H2 2016 39

Number of Products by Stage and Molecule Type, H2 2016 41

Uveal Melanoma – Dormant Projects, H2 2016 100

Uveal Melanoma – Discontinued Products, H2 2016 101

List of Figures

List of Figures

Number of Products under Development for Uveal Melanoma, H2 2016 10

Number of Products under Development for Uveal Melanoma – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 31

Number of Products by Top 10 Targets, H2 2016 32

Number of Products by Stage and Top 10 Targets, H2 2016 32

Number of Products by Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Routes of Administration, H2 2016 38

Number of Products by Stage and Routes of Administration, H2 2016 38

Number of Products by Molecule Types, H2 2016 40

Number of Products by Stage and Molecule Types, H2 2016 40

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports